Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have
relapsed or refractory lymphoma or leukemia. Drugs used in chemotherapy use different ways to
stop tumor cells from dividing so they stop growing or die